The European Commission has finalized its review of the proposed merger between Thermo Fisher and Clario, Case M.12264. The decision, issued on March 19, 2026, under Article 6(1)(b) of Council Regulation 139/2004, signifies the Commission's determination on the concentration.

This decision is binding and has implications for the companies involved in the merger. Regulated entities in the medical device manufacturing and healthcare sectors should note the Commission's assessment of this significant transaction. The provisional deadline for related actions was March 23, 2026.